New financing will enable the company to expand in the US its phase II clinical trial ACTIMIS for its drug candidate glenzocimab (ACT017) in acute ischemic stroke Acquisition of 100% of AVCare, a start-up developing a stroke biomarker. Paris, November 6th, 2019 - Acticor Biotech, a clinical stage biotechnology company involved in the acute phase […]

Paris, November 5th 2019 - Acticor Biotech, a clinical stage biotechnology company dedicated to the acute phase of thrombo-embolic diseases, including stroke, announces its participation to the BOOSTER consortium, dedicated to personalized medicine for the management of stroke in emergency situations. Led by Professor Mikael Mazighi from Paris University, who is neurologist at Lariboisière Hospital […]

Paris, October 16, 2018 - Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, today announced that it has completed a €15.3 million Series B round of financing from European and Asian investors. This new funding will enable the company to finance its first […]

Paris, July 31, 2018 - Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, announces the signature of an Asset Transfer and Licensing agreement covering a development and commercialisation collaboration agreement with CMS Medical Limited as well as an investment agreement with CMS Medical […]

Paris, June 14, 2018 - Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, as part of the development of its first drug candidate ACT017 who has just successfully completed a phase 1 study in the healthy volunteer, confided to Simbec-Orion carrying out his […]

Paris, April 25th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, has discussed with the European Medicines Agency (EMA) the development of its drug candidate, ACT017. This meeting follows the completion of the first-in-human study in January 2018 which provided preliminary […]